# NEST3: HCP commentary report

> 127 verified statements (81 from clinicians verified by NPI or staff page) from 23 commentary sources · 9 findings · updated Oct 29, 2026

## Report

- Trial: A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
- NCT ID: NCT07595874
- Registry: https://clinicaltrials.gov/study/NCT07595874
- Sponsor: City of Hope Medical Center
- Phase: Phase 2
- Status: Recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 205e3db92f95dc3477d780078199eb4f920c83997023ddf4c9d60823971c492f

## Counts

- HCP commentary sources screened: 35
- Sources cited by verified statements: 24
- Verified statements: 127
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 81
- Findings: 9
- People found in screened sources: 21
- Voices cited: 21
- Cited voices identity-verified: 10
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on NEST3 in the sources reviewed for this edition leads to one open question: What improvement in durable cure, at what immune-toxicity and surgical cost, would justify adding BOT/BAL before curative surgery? Its leading findings: (1) the threshold for practice change remains contested. (2) protecting curative surgery qualifies the enthusiasm for adding treatment. (3) durable cure matters more than pathological response alone. 6 more findings follow. 35 sources screened, 24 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What improvement in durable cure, at what immune-toxicity and surgical cost, would justify adding BOT/BAL before curative surgery?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The threshold for practice change remains contested
- F2. Protecting curative surgery qualifies the enthusiasm for adding treatment
- F3. Durable cure matters more than pathological response alone
- F4. The preoperative interval is a research hypothesis, not an established optimum
- F5. CT-based selection attracts confident advocacy, with a specific and limited staging task
- F6. Immune remodeling strengthens the activity rationale, but prediction remains unvalidated
- F7. ctDNA/MRD is proposed as an early readout, with DFS still required
- F8. Research access depends on travel, geography and affordability
- F9. Development speed is linked to funding and an uncertain neoadjuvant approval path

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 16 | 9 | 8 | 8 | recorded | 3 |
| F2 | 17 | 15 | 11 | 7 | recorded | 3 |
| F3 | 16 | 13 | 7 | 7 | recorded | 3 |
| F4 | 10 | 8 | 3 | 2 | none recorded | 3 |
| F5 | 11 | 6 | 3 | 2 | none recorded | 3 |
| F6 | 21 | 18 | 13 | 10 | recorded | 3 |
| F7 | 5 | 4 | 1 | 1 | none recorded | 3 |
| F8 | 14 | 14 | 8 | 6 | recorded | 3 |
| F9 | 21 | 15 | 10 | 7 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 11 | 2 | 0 | 3 | 0 | 17 | 0 | 7 posts and articles, 1 podcast or video | yes |
| F2 | 8 | 1 | 3 | 1 | 4 | 19 | 1 | 10 posts and articles, 1 podcast or video | yes |
| F3 | 11 | 3 | 0 | 1 | 1 | 17 | 0 | 5 posts and articles, 1 podcast or video, 1 registry | yes |
| F4 | 5 | 1 | 2 | 0 | 2 | 10 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F5 | 8 | 0 | 2 | 1 | 0 | 11 | 1 | 3 posts and articles | yes |
| F6 | 14 | 2 | 0 | 1 | 4 | 22 | 2 | 12 posts and articles, 1 podcast or video | yes |
| F7 | 3 | 1 | 0 | 0 | 1 | 7 | 0 | 1 podcast or video | yes |
| F8 | 10 | 0 | 0 | 0 | 4 | 16 | 0 | 7 posts and articles, 1 podcast or video | yes |
| F9 | 11 | 1 | 4 | 4 | 1 | 22 | 0 | 9 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Two-year disease-free survival rate: F1 (4 shared claims), F2 (2 shared claims), F3 (9 shared claims), F6 (1 shared claims), F7 (3 shared claims), F8 (2 shared claims), F9 (2 shared claims)
- Secondary endpoints: F1 (7 shared claims), F2 (14 shared claims), F3 (7 shared claims), F4 (4 shared claims), F6 (6 shared claims), F7 (2 shared claims)
- Population and setting: F1 (2 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (7 shared claims), F6 (5 shared claims), F8 (4 shared claims)
- The comparison: F1 (1 shared claims), F2 (5 shared claims), F4 (6 shared claims), F6 (2 shared claims), F9 (2 shared claims)
- Safety and tolerability: F1 (5 shared claims), F2 (12 shared claims), F3 (1 shared claims), F4 (2 shared claims), F6 (5 shared claims), F9 (1 shared claims)
- Design and conduct: F1 (6 shared claims), F2 (4 shared claims), F3 (3 shared claims), F4 (4 shared claims), F5 (2 shared claims), F6 (2 shared claims), F8 (4 shared claims), F9 (9 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 127 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 24 | Counts free |
| Speaker attribution for cited voices | 21 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Two-year disease-free survival rate | discussed | 14 | 6 |
| Secondary endpoints | discussed | 28 | 12 |
| Population and setting | discussed | 21 | 10 |
| The comparison | discussed | 15 | 6 |
| Safety and tolerability | discussed | 13 | 9 |
| Design and conduct | discussed | 24 | 13 |
| Earlier NEST immune remodeling and NEST3 predictive-marker research | discussed | 23 | 15 |
| CT staging, central review and possible overtreatment | discussed | 11 | 3 |
| Pathological-response interpretation and CRC ctDNA/MRD surrogacy | discussed | 11 | 2 |
| Referral, research access, affordability and geographic opportunity | discussed | 13 | 8 |
| Earlier-study lineage, funding and the neoadjuvant development pathway | discussed | 26 | 12 |
| Earlier NEST reception and patient-information expectations | discussed | 21 | 10 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 27 | 17 |
| LinkedIn posts | 7 | 5 |
| Podcasts | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2026-08-26 to 2026-10-01
- Cited window: 2026-08-26 to 2026-10-01
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
- Registry: NCT07595874 (https://clinicaltrials.gov/study/NCT07595874)
- Study IDs: 25964 · P30CA033572 · NCI-2026-02923 (CTRP (Clinical Trial Reporting Program))
- Sponsor: City of Hope Medical Center
- Collaborators: National Cancer Institute (NCI)
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Recruiting
- Enrollment: 100 (estimated)
- Start: 2026-07-01 (actual)
- Primary completion: 2028-12-16 (estimated)
- Primary endpoint: Two-year disease-free survival rate (At 2 years post enrollment)
- Intervention: Balstilimab (biological)
- Intervention: Biospecimen Collection (procedure)
- Intervention: Botensilimab (biological)
- Intervention: Computed Tomography (procedure)
- Intervention: Magnetic Resonance Imaging (procedure)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 41 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are selected public discussions, not a representative sample of HCP opinion. Reposts and relayed summaries do not constitute independent clinical observations or votes.
- Some discussions explicitly labeled NEST-1 or NEST2 were not examined, although earlier-program experience could inform the same treatment decision.
- No full NEST3 protocol, exact-trial results publication or exact product label was available among these sources. Earlier NEST activity must not be presented as NEST3 efficacy or an authorized-use determination.
- The material mixes confirmed individual identities, unverified identities and authors whose clinical roles are not established. Source descriptions of credentials are not independently confirmed credentials.
- Some episode remarks have no established speaker. They cannot be assigned to a named participant or counted as an additional person's agreement or disagreement.
- Reported response and survival figures are commentary restatements with differing patient, tumor and cohort denominators. Pathological response is not established here as a validated survival surrogate.
- Site availability, enrollment descriptions and plans reflect the time of the statements. Publication dates do not establish recording dates, study readout dates or changes of mind.
- Detailed NEST3 toxicity grades, surgical morbidity, patient-level affordability and validated predictive-marker performance are not provided; their absence from these statements is not evidence of absence.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition, corrected 2026-10-29
  - Correction 2026-10-29: Corrected to match the delivered report: per-finding counts. The trial's registration date is now stated.

Last checked for new commentary 2026-10-29. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (127 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (10 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/nest3-nct07595874
- Agents: POST https://www.erudio.com/api/orders with {"report": "nest3-nct07595874", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=nest3-07595874

## Cite

Erudio Health. NEST3 (NCT07595874): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/nest3-nct07595874

## Machine access

- JSON: https://www.erudio.com/reports/nest3-nct07595874.json
- Markdown: https://www.erudio.com/reports/nest3-nct07595874.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "nest3-07595874"}`